Bulk Inquiry
SR 27897
- Lintitript
Axon 1245
CAS:
136381-85-6
Purity:
99%
- Soluble in DMSO
- MF: C20H14ClN3O3S
- MW: 411.86
Description
SR 27897 is a potent and selective cholecystokinin CCK1 receptor antagonist.
CCK1 receptors regulate satiety, gallbladder contraction, pancreatic enzyme secretion and gastrointestinal motility. SR 27897 is used to block peripheral CCK1 receptor signaling and to study cholecystokinin physiology.
Key Features
- Potent selective CCK1 receptor antagonist
- Blocks cholecystokinin CCK-A receptor signaling
- Useful for gastrointestinal and appetite-related pharmacology
- Relevant to pancreatic secretion and motility studies
Applications
- CCK1 receptor binding and functional assays
- Gastrointestinal motility research
- Satiety and feeding pathway studies
- Cholecystokinin receptor subtype profiling
More Information
| Parent CAS No. | 136381-85-6 |
|---|---|
| Chemical Name | {2-[4-(2-Chloro-phenyl)-thiazol-2-ylcarbamoyl]-indol-1-yl}-acetic acid |
| SMILES | C1(C(NC2=NC(C3C=CC=CC=3Cl)=CS2)=O)N(CC(=O)O)C2C=CC=CC=2C=1 |
| MFCD | MFCD00868618 |
| InChi | InChI=1S/C20H14ClN3O3S/c21-14-7-3-2-6-13(14)15-11-28-20(22-15)23-19(27)17-9-12-5-1-4-8-16(12)24(17)10-18(25)26/h1-9,11H,10H2,(H,25,26)(H,22,23,27) |
| InChiKey | ILNRQFBVVQUOLP-UHFFFAOYSA-N |
| CID | 122077 |
| Short Description | CCK1 antagonist |
SR 27897
selective CCK1 receptor antagonist
Lintitript
SR27897
CCK1
CCK1 receptor
Antagonist
CCK1 receptor binding and functional assays
Gastrointestinal motility research
Satiety and feeding pathway studies
Cholecystokinin receptor subtype profiling
GPCR pharmacology
receptor selectivity
signal transduction
receptor pharmacology
enzyme pharmacology
drug discovery
CAS 136381-85-6
Axon Medchem
Axon 1245
Supplier
Vendor
References
- Gully et al. Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors. Eur. J. Pharmacol. 1993, 23, 232.
- Poncelet M. Et al. Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol. 1993, 348(1), 102-107.
